Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of $1.94, $0.77 better than the analyst estimate of $1.17. Revenue for the quarter came in at $811 million versus the consensus estimate of $766.85 million.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.